曲美拉莫用于难治性卵巢癌的II期试验。
Phase II trial of trimelamol in refractory ovarian cancer.
作者信息
Judson I R, Calvert A H, Gore M E, Balmanno K, Gumbrell L A, Perren T, Wiltshaw E
机构信息
Section of Drug Development, Institute of Cancer Research, Royal Marsden Hospital, UK.
出版信息
Br J Cancer. 1991 Feb;63(2):311-3. doi: 10.1038/bjc.1991.72.
Trimelamol is an analogue of hexamethymelamine which exhibited activity against refractory ovarian cancer in phase I clinical trial. The dose limiting toxicity was leukopenia. In a phase II study, 42 patients with recurrent, or platinum-complex resistant, advanced ovarian cancer were treated using the dose schedule 800 mg m-2 i.v. daily for 3 days. There were one complete, three partial and five minor responses, objective response rate: 9.5%. The main toxicity observed was nausea and vomiting, myelosuppression was minor. The role of Trimelamol in the treatment of ovarian cancer remains to be defined, but its activity is limited in refractory disease.
曲美拉莫是六甲蜜胺的类似物，在I期临床试验中显示出对难治性卵巢癌的活性。剂量限制性毒性是白细胞减少。在一项II期研究中，42例复发的、铂类复合物耐药的晚期卵巢癌患者采用每日800 mg/m²静脉注射，连用3天的给药方案进行治疗。有1例完全缓解、3例部分缓解和5例轻度缓解，客观缓解率为9.5%。观察到的主要毒性是恶心和呕吐，骨髓抑制较轻。曲美拉莫在卵巢癌治疗中的作用仍有待确定，但其在难治性疾病中的活性有限。
Zotero 插件